The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease

Carol Pollock, Anna Zuk, Hans Joachim Anders, Mohammad Reza Ganji, David W. Johnson, Bertram Kasiske, Robyn G. Langham, Roberto Pecoits-Filho, Giuseppe Remuzzi, Jerome Rossert, Yusuke Suzuki, Tetsuhiro Tanaka, Robert Walker, Chih Wei Yang, Joseph V. Bonventre

Research output: Contribution to journalReview ArticleResearchpeer-review

5 Citations (Scopus)


The focus of this article is to define goals and resulting action plans that can be collectively embraced by interested stakeholders to facilitate new therapeutic approaches to mitigate chronic kidney disease progression. The specific goals include identifying druggable targets, increasing the capacity for preclinical and early clinical development, broadening the availability of new therapeutic approaches, and increasing investment in the development of new therapies to limit chronic kidney disease. Key deliverables include the establishment of new regional, national, and global consortia; development of clinical trial networks; and creation of programs to support the temporary mutual movement of scientists between academia and the biotechnology and pharmaceutical sector. Other deliverables include cataloging and maintaining up-to-date records to collate progress in renal research and development, inventorying the capacity of research and clinical networks, and describing methods to ensure novel drug development.

Original languageEnglish
Pages (from-to)130-137
Number of pages8
JournalKidney International Supplements
Issue number2
Publication statusPublished - 1 Oct 2017


  • drug re-purposing
  • personalized medicine
  • targeted treatment

Cite this